Product Name:CJC-1295
Cas No:863288-34-0
Molar Mass:3367.90
Chemical Formula:C152H252N44O42
Synonyms:CID 56841945
Storage:Store at -20°C
Sequence: YADAIFTQSYRKVLAQLSARKLLQDILSR
Target Indicators: CJC-1295 acetate is used as a growth hormone-releasing hormone (GHRH) agonist and in the preparation of anti-aging agents
Target:GHRH
Purity: 98%
Application: CJC-1295, a synthetic peptide, is designed to stimulate the release of growth hormone from the pituitary gland. It belongs to the class of growth hormone-releasing peptides (GHRPs) and acts by mimicking the action of natural growth hormone-releasing hormone (GHRH). In pharmaceutical chemistry, CJC-1295 is studied for its potential in treating growth hormone deficiency and age-related decline in growth hormone secretion. It has gained attention in the field of sports medicine and performance enhancement due to its ability to increase muscle mass, improve recovery times, and enhance physical performance. Additionally, CJC-1295 is investigated for its potential in anti-aging therapies and improving overall well-being. Its mechanism of action in stimulating growth hormone release offers promising applications in various fields, including endocrinology, sports science, and age-related medicine.
Current Research:CJC-1295, a synthetic growth hormone-releasing hormone (GHRH) analog, has garnered attention for its potential therapeutic benefits in stimulating growth hormone (GH) and insulin-like growth factor-I (IGF-I) secretion. Pulsatile GH secretion is crucial for many physiological functions, and while short-term GHRH infusions have shown promise in enhancing GH pulsatility and increasing IGF-I, the limitations of GHRH’s short half-life hinder its therapeutic application. However, CJC-1295 addresses this limitation with its extended half-life of 8 days due to its permanent binding to endogenous albumin post-injection. Research aimed to assess GH pulsatility following a single injection of CJC-1295 and determine its correlation with IGF-I production increase. Results demonstrated that CJC-1295 administration led to increased GH secretion while preserving pulsatility, with both basal (trough) and mean GH levels significantly elevated. Despite the unaltered frequency and magnitude of GH secretory pulses, the overall GH secretion and subsequent IGF-I levels exhibited substantial increases. Notably, the marked enhancement of trough GH levels underscores the importance of continuous GHRH stimulation in augmenting IGF-I production. These findings suggest that long-acting GHRH preparations like CJC-1295 hold promise for clinical use, particularly in patients with intact pituitary GH secretory capability, offering a potential avenue for therapeutic intervention in conditions characterized by disrupted GH and IGF-I dynamics.
